Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Current Leases (2023 - 2025)

Telix Pharmaceuticals (TLX) posted Current Leases of $5.5 million for Q4 2025, up 239.89% on a QoQ basis from $1.6 million in Q4 2024, and up 239.89% year-over-year from $1.6 million in Q4 2024.

Telix Pharmaceuticals (TLX) has 3 years of Current Leases data on file, last reported at $5.5 million in Q4 2025.

  • In Q4 2025, Current Leases rose 239.89% year-over-year to $5.5 million; the TTM figure through Dec 2025 stood at $5.5 million (up 239.89% YoY), while the FY2025 annual figure was $5.5 million, up 258.86% from the prior year.
  • Current Leases rose to $5.5 million in Q4 2025, from $1.6 million in the prior quarter.
  • Across five years, Current Leases topped out at $5.5 million in Q4 2025 and bottomed at $387339.3 in Q4 2023.
  • A 3-year average of $2.5 million and a median of $1.6 million in 2024 frame the typical range for Current Leases.
  • Annual changes were most pronounced in 2024 — Current Leases soared 321.41% — and 2025, when it soared 239.89%.
  • Year by year, Current Leases stood at $387339.3 in 2023, then soared by 321.41% to $1.6 million in 2024, then soared by 239.89% to $5.5 million in 2025.
  • The last three Current Leases figures came in at $5.5 million (Q4 2025), $1.6 million (Q4 2024), and $387339.3 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Leases (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 83,991.00
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 7.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 720.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 45.66 Mn
10 Telix Pharmaceuticals 4.52 Bn 4.38 Bn - 5.55 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 5.55 Mn
Dec 31, 2024 1.63 Mn
Dec 31, 2023 387,339.34